Login / Signup

A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.

Laura SchäferNina Thom
Published in: Veterinary dermatology (2024)
Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • randomized controlled trial
  • study protocol
  • squamous cell carcinoma
  • pet ct
  • phase iii